Literature DB >> 1909199

N-nitro L-arginine causes coronary vasoconstriction and inhibits endothelium-dependent vasodilatation in anaesthetized greyhounds.

O L Woodman1, G J Dusting.   

Abstract

1. The effect of N-nitro-L-arginine (L-NNA), an inhibitor of nitric oxide biosynthesis, on large coronary artery diameter and coronary blood flow was examined in anaesthetized greyhounds. The effects of L-NNA on the coronary vascular responses to acetylcholine (ACh), glyceryl trinitrate (GTN) and 5-hydroxytryptamine (5-HT) were also assessed. 2. L-NNA (5 mg kg-1), infused into the left circumflex coronary artery, increased systemic mean arterial pressure and decreased the external diameter of the artery. Infusion of L-NNA decreased coronary blood flow in 5 of the 7 dogs tested and increased mean coronary resistance but neither of these effects was statistically significant. There was no change in heart rate. 3. Intra-arterial injection of both ACh (0.01-0.05 micrograms kg-1) and GTN (0.1-0.5 micrograms kg-1) increased large coronary artery diameter and coronary blood flow. Coronary vascular responses to the endothelium-dependent vasodilator ACh were significantly reduced by L-NNA, whereas the responses to the endothelium-independent vasodilator GTN were not significantly affected. 4. 5-HT (0.1 microgram kg-1, injected into the left circumflex coronary artery) decreased coronary artery diameter but increased coronary blood flow. After the administration of L-NNA the 5-HT-induced dilatation of the coronary resistance vessels was significantly attenuated whereas the constriction of the circumflex coronary artery was increased in 3 out of 3 dogs in which diameter could be measured, although the latter effect was not statistically significant. 5. These data indicate that L-NNA causes coronary and systemic vasoconstriction and selectively inhibits endothelium-dependent vasodilatation in the coronary circulation of the anaesthetized greyhound. Therefore endothelium-derived NO has an important role in the regulation of coronary vascular tone in the large arteries and the resistance vessels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909199      PMCID: PMC1908370          DOI: 10.1111/j.1476-5381.1991.tb09802.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

Review 1.  The endogenous nitrovasodilator produced by the vascular endothelium.

Authors:  G J Dusting; P S Macdonald; E A Higgs; S Moncada
Journal:  Aust N Z J Med       Date:  1989-10

2.  Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man.

Authors:  P Vallance; J Collier; S Moncada
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

3.  Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation.

Authors:  B J Whittle; J Lopez-Belmonte; D D Rees
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

4.  Vascular endothelial cells synthesize nitric oxide from L-arginine.

Authors:  R M Palmer; D S Ashton; S Moncada
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

5.  Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin.

Authors:  T M Cocks; J A Angus
Journal:  Nature       Date:  1983 Oct 13-19       Impact factor: 49.962

6.  Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110.

Authors:  J B Habib; C Bossaller; S Wells; C Williams; J D Morrisett; P D Henry
Journal:  Circ Res       Date:  1986-02       Impact factor: 17.367

7.  Role of endothelium-derived nitric oxide in the regulation of blood pressure.

Authors:  D D Rees; R M Palmer; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits.

Authors:  T J Verbeuren; F H Jordaens; L L Zonnekeyn; C E Van Hove; M C Coene; A G Herman
Journal:  Circ Res       Date:  1986-04       Impact factor: 17.367

9.  Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta.

Authors:  C Bossaller; G B Habib; H Yamamoto; C Williams; S Wells; P D Henry
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

10.  Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit.

Authors:  J L Amezcua; R M Palmer; B M de Souza; S Moncada
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

View more
  5 in total

1.  Myogenic and flow-dependent control mechanisms in the coronary microcirculation.

Authors:  C J Jones; L Kuo; M J Davis; W M Chilian
Journal:  Basic Res Cardiol       Date:  1993 Jan-Feb       Impact factor: 17.165

2.  Complex stenosis morphology and vasomotor responses to inhibition of nitric oxide synthesis.

Authors:  D Tousoulis; C Tentolouris; T Crake; G Goumas; C Stefanadis; P Toutouzas; G Davies
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

3.  Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.

Authors:  A A Quyyumi; N Dakak; N P Andrews; S Husain; S Arora; D M Gilligan; J A Panza; R O Cannon
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

4.  The effects of N omega-nitro-L-arginine methyl ester, sodium nitroprusside and noradrenaline on venous return in the anaesthetized cat.

Authors:  E A Bower; A C Law
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Enhancement of noradrenergic constriction of large coronary arteries by inhibition of nitric oxide synthesis in anaesthetized dogs.

Authors:  O L Woodman; P Pannangpetch
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.